Trump signs executive order on drug pricing via 'most favored nation' model, GSK acquires $1.2B MASH program, Bayer cuts 2,000 jobs, and first CRISPR therapy treats infant.

The US Supreme Court should decline to review a generic drug labeling fight between Amarin and Hikma Pharmaceuticals because ...

The government 'did not act contrary to the law' by requiring drugmakers to seek approval before implementing proposed new ...

Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the use of its Duchenne muscular dystrophy gene ...

The Trump administration is partnering with Mark Cuban’s compounding business and four other entities to improve the ...

American Society of Gene & Cell Therapy meeting sees 10% drop in attendance. Notable absences include FDA officials, David ...

FDA lifts hold on Scynexis' ibrexafungerp Phase 3 fungal infection trial, but GSK plans to end study. Incyte's Zynyz gets FDA ...

BioMarin plans to buy Boston-based Inozyme Pharma and its Phase 3 enzyme replacement therapy for about $270 million, the ...

Leo Pharma is doing an extensive revamp of its leadership team as it splits product strategy and international operations ...

Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a 'pivot point' as the Trump ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored ...